RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lymphoma: experimental combo targets relapsed patients
Disease control Recruiting nowThis study tests whether adding the experimental drug HMPL-760 to standard chemotherapy (R-GemOx) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) live longer without their cancer getting worse. About 240 adults who have already tried other treatment…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Hutchmed • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New combo aims to boost transplant success in tough lymphoma
Disease control Recruiting nowThis study tests a lower dose of the drug epcoritamab combined with chemotherapy (gemcitabine and oxaliplatin) in people with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink tumors enough to a…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Hospital Universitario Dr. Jose E. Gonzalez • Aim: Disease control
Last updated May 08, 2026 12:02 UTC